Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

3 Small-Cap Stocks We Keep Off Our Radar

By: StockStory

May 18, 2026 at 00:36 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

WH Cover Image

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here are three small-cap stocks to swipe left on and some alternatives you should look into instead.

Wyndham (WH)

Market Cap: $5.97 billion

Established in 1981, Wyndham (NYSE: WH) is a global hotel franchising company with over 9,000 hotels across nearly 95 countries on six continents.

Why Are We Out on WH?

Revenue per room has underperformed over the past two years, suggesting it may need to develop new facilities
Low returns on capital reflect management’s struggle to allocate funds effectively, and its shrinking returns suggest its past profit sources are losing steam
Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

Wyndham is trading at $79.76 per share, or 16.7x forward P/E. If you’re considering WH for your portfolio, see our FREE research report to learn more.

KBR (KBR)

Market Cap: $3.81 billion

Known for projects like the construction of Guantanamo Bay, KBR provides professional services and technologies, specializing in engineering, construction, and government services sectors.

Why Is KBR Not Exciting?

Backlog has dropped by 1.2% on average over the past two years, suggesting it’s losing orders as competition picks up
Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 6.1%
Operating margin of 6.9% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments

KBR’s stock price of $30.09 implies a valuation ratio of 7.6x forward P/E. Read our free research report to see why you should think twice about including KBR in your portfolio.

Tandem Diabetes (TNDM)

Market Cap: $878.5 million

With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ: TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels.

Why Do We Think TNDM Will Underperform?

Earnings per share fell by 19.1% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
Push for growth has led to negative returns on capital, signaling value destruction, and its decreasing returns suggest its historical profit centers are aging
Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $12.62 per share, Tandem Diabetes trades at 16.1x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than TNDM.

Stocks We Like More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	264.14	+0.00 (0.00%)
AAPL	300.23	+0.00 (0.00%)
AMD	424.10	+0.00 (0.00%)
BAC	49.77	+0.00 (0.00%)
GOOG	393.32	+0.00 (0.00%)
META	614.23	+0.00 (0.00%)
MSFT	421.92	+0.00 (0.00%)
NVDA	225.32	+0.00 (0.00%)
ORCL	192.95	+0.00 (0.00%)
TSLA	422.24	+0.00 (0.00%)